Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
about
Research priorities in pharmacokineticsSobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology ModelsLeveraging systems biology approaches in clinical pharmacologyModeling and simulation at the interface of nonclinical and early clinical drug developmentEffect of disease states on α1 -adrenoceptor binding and signal transduction parameters in isolated perfused heart: quantification by pharmacokinetic-pharmacodynamic modelling.Scaling and systems biology for integrating multiple organs-on-a-chip.Integrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease.Integration of PKPD relationships into benefit-risk analysisParameter Identifiability of Fundamental Pharmacodynamic ModelsebTrack: an environmental bioinformatics system built upon ArrayTrackPopulation Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorA mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in ratsA three-parameter two-state model of receptor function that incorporates affinity, efficacy, and signal amplification.Comparison of methods for evaluating drug-drug interaction.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesTowards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Application of a mechanism-based disease systems model for osteoporosis to clinical data.Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.Coping with time scales in disease systems analysis: application to bone remodelingUricases as therapeutic agents to treat refractory gout: Current states and future directions.Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine.Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.Modeling NSCLC progression: recent advances and opportunities availableEngineering challenges for instrumenting and controlling integrated organ-on-chip systems.Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjectsScaling pharmacodynamics from in vitro and preclinical animal studies to humans.Development of translational pharmacokinetic-pharmacodynamic modelsModelling of alpha1-adrenoceptor-mediated temporal dynamics of inotropic response in rat heart to assess ligand binding and signal transduction parameters.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenEffects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs.Endpoints in pediatric pain studies.Advances in paediatric pharmacokinetics.Understanding the time course of pharmacological effect: a PKPD approach.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.
P2860
Q24633381-A6883E5D-5C55-465D-BF26-11772DD32FA9Q26779458-75CC64C3-A499-4E42-8CF9-C50CA250F77CQ28539118-B13590FB-3555-4D2F-A985-44939FD62C07Q28709672-F939512F-FAB3-4F0A-B2DD-0E9A37AAC9ABQ30317605-93666DB6-990D-4AA2-92FE-6F20FF08B6C8Q30410626-9CE89A97-602F-4C94-9648-FD684F92C718Q30422271-5C04232E-3DD8-4FC7-8C9A-64106C033E0AQ30671571-3D17233C-006F-48AB-96AA-D851F0A48BD5Q30830719-04394C91-FCC5-4886-92BD-33D6C8331C54Q33417131-AD5EC069-34B1-4731-8AF8-4732A9E95867Q33432047-E5C4A906-DB37-42D2-84AD-F8F2D06FCD8BQ33567046-14836BE2-B983-4CC9-8215-DA0DB93FA7C7Q33777942-C89D18C8-C0E2-4E5B-913E-D2289653AF77Q33914266-DAD0A414-AFFA-404A-830C-00A28F65B9E1Q34293689-EEC04A26-0B79-4C01-8234-D2D4B74F4CDFQ34393200-82523CF5-7185-4FF7-AC74-E040346A027DQ34475498-2135DDCF-FF73-4AC2-8EF6-FBD6A7EDF2AEQ34546981-270D5DD4-2A7D-43B2-ACBE-797605839477Q35206798-6B86421F-0687-4461-B545-95B3EF1DD639Q35591581-4E5AC5B6-7D53-456C-9938-79A886D4D1F9Q36002499-155B84ED-4669-4127-B081-EED6C7965907Q36090728-937A0743-1FCF-4626-83F0-B6ECB9B743CCQ36410253-E90CA8A2-7B89-4841-A74D-A54A62FB9824Q36697929-9DAE784A-A44A-41FB-A42E-D34E4E99A2ECQ36702365-8FF62A0C-5B8E-47A0-9977-88BF5090A030Q36909252-9A856852-EE44-4A5E-BE32-B1F1325F4856Q36910615-1206A045-5DA8-4FA1-8917-57D565AC0614Q36968126-7F2FBA22-6A7C-4D02-BB05-955A7ACC8A94Q37030723-DC627CEE-AE12-4888-86C6-CECE655864FCQ37055123-4857BDE9-B2B5-459C-AA3A-AC56DE473E78Q37128660-8B06FBA2-8D53-4436-BECF-9CF3485982D1Q37230836-B9E899E2-2D84-452C-BF62-21EDF30FAD1FQ37279407-1446C916-6B88-432B-95B8-B19D13D5B11EQ37521097-B85DC095-3314-47E8-ACF2-23FE0C90D1FAQ37521422-9BB2B7D8-1658-40D0-854F-53675A98638DQ37573381-97813D54-1502-49DD-BA43-DA3B1E08687BQ37812309-05D792A7-81E6-496C-AAF4-5CA93EB2B788Q37813680-9F8BC24A-C7FF-443A-A203-A7A632DA73ABQ37832754-A2302D6E-1C9C-4DF2-9349-7E2BF723CC1AQ37886138-CEC3D848-BDAF-433D-AF6D-FBBFB61F2A38
P2860
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@ast
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@en
type
label
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@ast
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@en
prefLabel
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@ast
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@en
P2093
P1476
Mechanism-based pharmacokineti ...... nd dynamical systems analysis.
@en
P2093
Bart A Ploeger
Elizabeth C M De Lange
Joost de Jongh
Meindert Danhof
Oscar Della Pasqua
Rob A Voskuyl
P304
P356
10.1146/ANNUREV.PHARMTOX.47.120505.105154
P577
2007-01-01T00:00:00Z